Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology

Oncotarget

Volumn 8, Issue 19, 2017, Pages 30830-30843

  Khan, Shahanavaj ^a,b   Zakariah, Mohammed ^c   Rolfo, Christian ^d   Robrecht, Lembrechts ^d   Palaniappan, Sellappan ^e  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Shri Ram Group of Colleges   (India)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e MALAYSIA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Malaysia)

Author keywords

Cytoplasm; Database; M. hominis; Mitochondria; Prostate cancer

Indexed keywords

PROTEOME; BACTERIAL PROTEIN; PROTEIN BINDING;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CELLULAR DISTRIBUTION; CHRONIC INFLAMMATION; CYTOPLASM; HOST CELL; METABOLISM; MITOCHONDRION; MOLECULAR WEIGHT; MYCOPLASMA HOMINIS INFECTION; NUCLEAR LOCALIZATION SIGNAL; PREDICTION; PROSTATE CANCER; PROTEIN TARGETING; BIOLOGY; CELL TRANSFORMATION; COMPLICATION; COMPUTER SIMULATION; HOST PATHOGEN INTERACTION; HUMAN; MALE; MICROBIOLOGY; MYCOPLASMA HOMINIS; MYCOPLASMA INFECTION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROSTATE TUMOR; PROTEIN TRANSPORT;

BACTERIAL PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYTOPLASM; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MITOCHONDRIA; MYCOPLASMA HOMINIS; MYCOPLASMA INFECTIONS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT;

EID: 85019078234     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8306     Document Type: Article

References (86)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
3. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69
5. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006;124:823-35
6. Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep 2008;9:243-9
7. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-3
8. Lanoix JP, Pluquet E, Lescure FX, Bentayeb H, Lecuyer E, Boutemy M, Dumont P, Jounieaux V, Schmit JL, Dayen C, Douadi Y. Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis 2011;11:183
9. Barykova YA, Logunov DY, Shmarov MM, Vinarov AZ, Fiev DN, Vinarova NA, Rakovskaya IV, Baker PS, Shyshynova I, Stephenson AJ, Klein EA, Naroditsky BS, Gintsburg AL, et al. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget 2011;2:289-97. doi: 10.18632/oncotarget.256
10. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007;100:733-7
11. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M, Schlomm T. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 2008;43:277-83
12. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998;62:1094-156
13. Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and different human carcinomas. World J Gastroenterol 2001;7:266-9
14. Cimolai N. Do mycoplasmas cause human cancer? Can J Microbiol 2001;47:691-7
15. Dessi D, Delogu G, Emonte E, Catania MR, Fiori PL, Rappelli P. Long-term survival and intracellular replication of Mycoplasma hominis in Trichomonas vaginalis cells: potential role of the protozoon in transmitting bacterial infection. Infect Immun 2005;73:1180-6
16. Barykova Iu A, Shmarov MM, Logunov D, Verkhovskaia LV, Aliaev Iu G, Fiev DN, Vinarov AZ, Vinarova NA, Rakovskaia IV, Naroditskii BS, Gudkov AV, Gintsburg AL. [Identification of Mycoplasma in patients with suspected prostate cancer]. Zh Mikrobiol Epidemiol Immunobiol 2010:81-5
17. Lo SC, Tsai S. Mycoplasmas and human prostate cancer: an exciting but cautionary note. Oncotarget 2011;2:352-5. doi: 10.18632/oncotarget.282
18. Feng SH, Tsai S, Rodriguez J, Lo SC. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol 1999;19:7995-8002
19. Tsai S, Wear DJ, Shih JW, Lo SC. Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci U S A 1995;92:10197-201
20. Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014;11:197-212
21. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215
22. Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One 2009;4:e6872
23. Calcutt MJ, Foecking MF. Analysis of the Complete Mycoplasma hominis LBD-4 Genome Sequence Reveals Strain-Variable Prophage Insertion and Distinctive Repeat-Containing Surface Protein Arrangements. Genome Announc 2015;3
24. Coiras M, Camafeita E, Lopez-Huertas MR, Calvo E, Lopez JA, Alcami J. Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics 2008;8:852-73
25. Silmon de Monerri NC, Kim K. Pathogens hijack the epigenome: a new twist on host-pathogen interactions. Am J Pathol 2014;184:897-911
26. Prudencio M, Lehmann MJ. Illuminating the host-how RNAi screens shed light on host-pathogen interactions. Biotechnol J 2009;4:826-37
27. Hopfe M, Deenen R, Degrandi D, Kohrer K, Henrich B. Host cell responses to persistent mycoplasmas-different stages in infection of HeLa cells with Mycoplasma hominis. PLoS One 2013;8:e54219
28. Wan XF, Branton SL, Collier SD, Evans JD, Leigh SA, Pharr GT. Proteomics inference of genes involved in host adaptation of Mycoplasma gallinarum. Vet Microbiol 2010;145:177-84
29. Chernov VM, Chernova OA, Sanchez-Vega JT, Kolpakov AI, Ilinskaya ON. Mycoplasma Contamination of Cell Cultures: Vesicular Traffic in Bacteria and Control over Infectious Agents. Acta Naturae 2014;6:41-51
30. Rogers MB. Mycoplasma and cancer: in search of the link. Oncotarget 2011;2:271-3. doi: 10.18632/oncotarget.264
31. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 2004;32:D115-9
32. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, Pilbout S, Schneider M. The SWISSPROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 2003;31:365-70
33. Wu CH, Yeh LS, Huang H, Arminski L, Castro-Alvear J, Chen Y, Hu Z, Kourtesis P, Ledley RS, Suzek BE, Vinayaka CR, Zhang J, Barker WC. The Protein Information Resource. Nucleic Acids Res 2003;31:345-7
34. Consortium U. Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 2013;41:D43-7
35. Pereyre S, Sirand-Pugnet P, Beven L, Charron A, Renaudin H, Barre A, Avenaud P, Jacob D, Couloux A, Barbe V, de Daruvar A, Blanchard A, Bebear C. Life on arginine for Mycoplasma hominis: clues from its minimal genome and comparison with other human urogenital mycoplasmas. PLoS Genet 2009;5:e1000677
36. Pierleoni A, Martelli PL, Fariselli P, Casadio R. BaCelLo: a balanced subcellular localization predictor. Bioinformatics 2006;22:e408-16
37. Wallace DC. Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. Annu Rev Biochem 2007;76:781-821
38. Lane N, Martin W. The energetics of genome complexity. Nature 2010;467:929-34
39. Knizewski L, Ginalski K. Bacterial DUF199/COG1481 proteins including sporulation regulator WhiA are distant homologs of LAGLIDADG homing endonucleases that retained only DNA binding. Cell Cycle 2007;6:1666-70
40. Stoddard BL. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. Structure 2011;19:7-15
41. West SC. Processing of recombination intermediates by the RuvABC proteins. Annu Rev Genet 1997;31:213-44
42. Ip SC, Rass U, Blanco MG, Flynn HR, Skehel JM, West SC. Identification of Holliday junction resolvases from humans and yeast. Nature 2008;456:357-61
43. Akey DL, Berger JM. Structure of the nuclease domain of ribonuclease III from M. tuberculosis at 2.1 A. Protein Sci 2005;14:2744-50
44. Nicholson AW. Ribonuclease III mechanisms of doublestranded RNA cleavage. Wiley Interdiscip Rev RNA 2014;5:31-48
45. Ramotar D. The apurinic-apyrimidinic endonuclease IV family of DNA repair enzymes. Biochem Cell Biol 1997;75:327-36
46. Hosfield DJ, Guan Y, Haas BJ, Cunningham RP, Tainer JA. Structure of the DNA repair enzyme endonuclease IV and its DNA complex: double-nucleotide flipping at abasic sites and three-metal-ion catalysis. Cell 1999;98:397-408
47. Coller HA. Is cancer a metabolic disease? Am J Pathol 2014;184:4-17
48. Johnson SM. The importance of B-cells and ecto-5'nucleotidase in Mycoplasma fermentans infection and the relevance to rheumatoid arthritis. Immunology 2008;123:187-96
49. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9
50. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-30
51. Warburg O. On the origin of cancer cells. Science 1956;123:309-14
52. Shchemelinin I, Sefc L, Necas E. Protein kinases, their function and implication in cancer and other diseases. Folia Biol (Praha) 2006;52:81-100
53. Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65:1-5
54. Robertson JF, O'Neill KL, Thomas MW, McKenna PG, Blamey RW. Thymidine kinase in breast cancer. Br J Cancer 1990;62:663-7
55. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33
56. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 2013;45:e45
57. Yang W, Lu Z. Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett 2013;339:153-8
58. Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J Biol Chem 2008;283:1563-71
59. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 2009;8:1037-44
60. Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer 2011;11:708-18
61. Kim D, Kwon NH, Kim S. Association of aminoacyl-tRNA synthetases with cancer. Top Curr Chem 2014;344:207-45
62. Perez I, Blanco L, Sanz B, Errarte P, Ariz U, Beitia M, Fernandez A, Loizate A, Candenas ML, Pinto FM, Gil J, Lopez JI, Larrinaga G. Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer. Int J Med Sci 2015;12:458-67
63. Selvakumar P, Lakshmikuttyamma A, Dimmock JR, Sharma RK. Methionine aminopeptidase 2 and cancer. Biochim Biophys Acta 2006;1765:148-54
64. Copeland RA. Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res 2013;19:6344-50
65. Sasaki M, Kaneuchi M, Sakuragi N, Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res 2003;63:3101-6
66. Yager JD. Catechol-methyltransferase: characteristics, polymorphisms and role in breast cancer. Drug Discov Today Dis Mech 2012;9:e41-e46
67. di Salvo ML, Contestabile R, Paiardini A, Maras B. Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. Med Hypotheses 2013;80:633-6
68. Johnson LF, Levis R, Abelson HT, Green H, Penman S. Changes in RNA in relation to growth of the fibroblast. IV. Alterations in theproduction and processing of mRNA and rRNA in resting and growing cells. J Cell Biol 1976;71:933-8
69. Colina R, Costa-Mattioli M, Dowling RJ, Jaramillo M, Tai LH, Breitbach CJ, Martineau Y, Larsson O, Rong L, Svitkin YV, Makrigiannis AP, Bell JC, Sonenberg N. Translational control of the innate immune response through IRF-7. Nature 2008;452:323-8
70. Topisirovic I, Sonenberg N. mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. Cold Spring Harb Symp Quant Biol 2011;76:355-67
71. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
72. Wurth L. Versatility of RNA-Binding Proteins in Cancer. Comp Funct Genomics 2012;2012:178525
73. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011;11:644-56
74. Takaku H, Minagawa A, Takagi M, Nashimoto M. A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. Nucleic Acids Res 2003;31:2272-8
75. Ruggero D. Translational control in cancer etiology. Cold Spring Harb Perspect Biol 2013;5
76. Loreni F, Mancino M, Biffo S. Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogene 2014;33:2145-56
77. Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov 2015;14:261-78
78. Grzmil M, Hemmings BA. Translation regulation as a therapeutic target in cancer. Cancer Res 2012;72:3891-900
79. Calderwood SK, Gong J. Molecular chaperones in mammary cancer growth and breast tumor therapy. J Cell Biochem 2012;113:1096-103
80. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006;31:164-72
81. Hessenkemper W, Baniahmad A. Targeting heat shock proteins in prostate cancer. Curr Med Chem 2013;20:2731-40
82. Graner MW, Cumming RI, Bigner DD. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J Neurosci 2007;27:11214-27
83. Van Drie JH. Protein folding, protein homeostasis, and cancer. Chin J Cancer 2011;30:124-37
84. Azad AA, Zoubeidi A, Gleave ME, Chi KN. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol 2015;12:26-36
85. Khan AA, Khan Z, Malik A, Shrivastava A, Jain SK, Alshamsan A. Computational prediction of Escherichia coli proteins host subcellular targeting and their implications in colorectal cancer etiology. Cancer Lett 2015;364:25-32
86. Kosugi S, Hasebe M, Tomita M, Yanagawa H. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci U S A 2009;106:10171-6